Jake Nunn

SR One is the corporate venture capital arm of GlaxoSmithKline.

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

Raised $318,000,000.00 from Longitude Capital, Superstring Capital, Enavate Sciences, Fairmount Funds Management, Wellington Management, Rock Springs Capital, Federated Hermes, Quan Capital, Delos Capital and Pivotal bioVenture Partners.

Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.

Raised $480,899,992.00 from New Enterprise Associates, Vivo Capital, Octagon Capital Advisors, Federated Hermes, Deep Track Capital, Adage Capital Management, RA Capital Management, Federated Kaufmann Fund, New Enterprise Associates and New Enterprise Associates.

Trevena is a clinical stage biopharmaceutical company discovering and developing G-protein coupled receptors (GPCR) biased ligands.

Raised $548,582,250.00 from R-Bridge, CBC Group, Square 1 Bank and Oxford Finance LLC.

clinical stage pharmaceutical company.

Raised $9,200,000.00 from National Heart, Lung and Blood Institute, Regenerative Medicine Minnesota, U.S. Department of Defense, National Institutes of Health and U.S. Department of Defense.

New Enterprise Associates is a venture capital firm that focuses on investments in technology and healthcare startups.